Surrozen, Inc./DE (SRZN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 9.01M USD | Liabilities, Current |
| Cash and equivalents | 102.04M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 5.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $9.01M | $102.04M | (m) | $5.00M | (m) | (m) |
| 2026-03-31 | (m) | $9.56M | $106.91M | (m) | $5.00M | (m) | (m) |
| 2025-12-31 | (m) | $9.93M | $89.25M | (m) | $0.00 | (m) | (m) |
| 2025-09-30 | (m) | $6.53M | $81.33M | (m) | $2.32M | (m) | (m) |
| 2025-06-30 | (m) | $5.74M | $90.39M | (m) | $2.32M | (m) | (m) |
| 2025-03-31 | (m) | $10.58M | $101.64M | (m) | $2.13M | (m) | (m) |
| 2024-12-31 | (m) | $7.32M | $34.56M | (m) | $2.04M | (m) | (m) |
| 2024-09-30 | (m) | $6.12M | $31.01M | (m) | $12.20M | (m) | (m) |
| 2024-06-30 | (m) | $5.98M | $37.77M | (m) | $2.11M | (m) | (m) |
| 2024-03-31 | (m) | $6.18M | $27.29M | (m) | $2.13M | (m) | (m) |
| 2023-12-31 | $38.20M | $7.15M | $36.04M | $0.00 | $2.15M | (m) | 5.34× |
| 2023-09-30 | $45.41M | $6.67M | $33.98M | $9.46M | $1.98M | (m) | 6.81× |
| 2023-06-30 | $55.37M | $6.45M | $36.50M | $16.90M | $1.98M | (m) | 8.58× |
| 2023-03-31 | $63.72M | $7.79M | $27.81M | $33.94M | $1.98M | (m) | 8.18× |
| 2022-12-31 | $77.82M | $9.73M | $24.69M | $51.15M | $1.98M | (m) | 8.00× |
| 2022-09-30 | (m) | $8.65M | $25.53M | $52.86M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $8.52M | $16.87M | $75.82M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $8.12M | $14.30M | $78.21M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $13.57M | $33.09M | $68.76M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $12.54M | $61.10M | $49.07M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $1.54M | $390.67K | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $986.59K | $774.93K | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $987.19K | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $30.65K | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |